Document is current
Any future updates will be listed below
-
Authors
Shin, Daeun
Lee, Sungjoo https://orcid.org/0000-0003-3564-4220
Kim, Jun Pyo https://orcid.org/0000-0003-4376-3107
Jang, Hyemin
Yun, Jihwan
Chun, Min Young
Ahn, Jehyun
Kim, Seongmi
Kim, Kyoungmin https://orcid.org/0009-0000-4161-3573
Yoon, Soyeon
Kim, Hee Jin
Kang, Heekyoung
Yim, Sohyun https://orcid.org/0000-0002-9357-768X
Park, Hee Kyung
Kim, Seonghyeon
Na, Duk L. https://orcid.org/0000-0002-0098-7592
Zetterberg, Henrik https://orcid.org/0000-0003-3930-4354
Blennow, Kaj https://orcid.org/0000-0002-1890-4193
Gonzalez-Ortiz, Fernando https://orcid.org/0000-0001-7897-9456
Ashton, Nicholas J. https://orcid.org/0000-0002-3579-8804
Weiner, Michael W.
Seo, Sang Won https://orcid.org/0000-0002-8747-0122
Kim, Kyunga https://orcid.org/0000-0002-0865-2236
- License Information
-
More Information
Article History
Received: 6 September 2025
Accepted: 14 January 2026
First Online: 2 February 2026
Competing interests
: H.Z. has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has delivered lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). Kaj Blennow has served as a consultant and on advisory boards for Abbvie, AC Immune, ALZPath, AriBio, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served on data monitoring committees for Julius Clinical and Novartis; has delivered lectures, produced educational materials, and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. The remaining authors declare no competing interests.
